All In Biotech

Free tool

FAERS Monitor: Hetlioz

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 205677 or its brand name (Hetlioz, Tasimelteon). Reports on generic versions are filed under their own applications.

Reports

5,773

Serious

600

10% of reports

Hospitalization

287

Death reported

166

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug ineffective1,636
  • insomnia730
  • product dose omission issue475
  • middle insomnia412
  • somnolence409
  • headache386
  • nightmare268
  • abnormal dreams224
  • fatigue224
  • therapeutic product effect decreased193
  • sleep disorder189
  • inappropriate schedule of product administration185
  • incorrect product administration duration165
  • poor quality sleep155
  • initial insomnia152

Reports by year received

View as table
YearReports
20149
2015577
2016408
2017308
2018540
2019776
2020741
2021730
2022550
2023559
2024331
2025150
202694

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,048,386 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
middle insomniaSignal41282.274.832,262
initial insomniaSignal15254.846.87,856
abnormal dreamsSignal22429.826.26,161
nightmareSignal26828.425.37,023
incorrect product administration durationSignal16528.024.04,233
poor quality sleepSignal15526.422.63,741
therapeutic product effect decreasedSignal19315.813.72,648
insomniaSignal73010.09.45,971
sleep disorderSignal1899.88.51,482
somnolenceSignal4097.46.82,280
product dose omission issueSignal4755.95.41,949
drug ineffectiveSignal1,6364.54.34,786
inappropriate schedule of product administrationSignal1853.73.2372
headacheSignal3862.22.0273
fatigue2241.00.90

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.